Introduction
Cell4Cure AB, a Swedish biotech company founded in 2023, is pioneering with a platform technology for development of immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company’s proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific immune tolerance.
These tolerogenic DCs bring a novel and widely applicable solution to mitigating or eliminating unwanted immune responses while preserving essential immune functions.
Cell4Cure’s primary focus is on Anti-Drug Antibodies (ADAs), a critical issue in conditions like severe hemophilia A, where 30% of patients develop neutralizing antibodies against factor VIII (FVIII) treatments.
We now broadly offer our platform solution to companies looking to overcome these costly therapeutic challenges where the effect of immunogenicity is a well-researched limitation.
In parallel to the platform advances, our lead product, ItolDC-028, is positioned to enter a Phase 1/2a clinical trial targeting hemophilia A patients who have developed these ADAs against factor VIII (FVIII).
Vision
& mission
Offer curative or correcting personalized cell therapies mediating antigen-specific tolerance via our proprietary technology platform
Provide solutions for severe clinical challenges in complex medical conditions
-
Anti-Drug Antibodies (ADAs)
-
Autoimmune Diseases
-
Transplant Rejections
Develop innovative alternatives to general immunosuppressive treatments to minimize their associated side effects, such as cancer and severe infections.
By focusing on achieving antigen-specific tolerance, our company strives to revolutionize the field and drive advancements in the treatment of these complex medical conditions, ultimately improving the quality of life for diverse patient groups.
